Cengild Medical Bhd

Cengild Medical Bhd maintains a strong liquidity position, with a current ratio of 8.08, indicating a substantial buffer of current assets over current liabilities. However, the company reported negative operating cash flow of MYR -1.672 million, which may signal short-term cash flow challenges despite the high current ratio. Free cash flow is minimal at MYR 34,000, suggesting limited capacity for reinvestment or shareholder returns. The debt-to-equity ratio of 0.13 reflects a conservative capital structure, with long-term debt at MYR 13.941 million compared to total equity of MYR 109.718 million.

Profitability metrics show a return on equity (ROE) of 2.77% and a return on assets (ROA) of 2.23%, both below the industry median for healthcare facilities and services. The net income of MYR 3.041 million on revenue of MYR 17.051 million yields a net margin of 17.83%, which is relatively strong but must be compared to industry benchmarks to assess competitive positioning.

The company's revenue is not segmented by product or geography in the available data, but the high concentration of revenue in a single business model (medical services and pharmaceuticals) suggests potential exposure to sector-specific risks. The lack of geographic diversification may limit resilience in the face of regional economic or regulatory shifts.

Looking ahead, the company's revenue outlook is constrained by the current operating cash flow challenges and limited free cash flow. While the capital expenditure of MYR -2.111 million indicates ongoing investment, the scale of these expenditures relative to revenue and cash reserves is modest. The company's growth trajectory will depend on its ability to convert operating income into sustainable cash flow.

The risk assessment highlights a medium liquidity risk due to the negative operating cash flow and low free cash flow, despite the high current ratio. The dilution risk is assessed as low, with no significant dilution potential identified in the basic shares outstanding. However, the negative net cash position after subtracting total debt raises concerns about short-term liquidity.

Recent filings and transcripts do not provide additional insights into the company's strategic direction or operational performance. The absence of recent material events or disclosures suggests a stable but potentially stagnant business environment for Cengild Medical Bhd.

Revenue grew 19.7% year-over-year to MYR 79.99 million, showing strong top-line expansion despite flat net income growth.

Debt-to-equity ratio of 0.13 is well below the cohort median of 0.32, reflecting a conservative and low-leverage capital structure.

The company maintains a low dilution risk profile, suggesting limited threat to existing shareholder equity value from share issuance.

Cash conversion ratio of -0.55 places the company in the bottom quartile of its healthcare cohort peers.

Long-term debt surged to MYR 47.55 million in the latest period, nearly tripling from the previous year's MYR 8.14 million.

The company faces medium liquidity and credit risks, highlighting potential challenges in meeting short-term obligations and debt servicing.

Revenue MYR 70.3M, +9,1% YoY; Operating income +39,7% YoY.

• ▍Revenue MYR 70.3M, +9,1% YoY
• ▍Operating income +39,7% YoY
• ▍Net income +41,5% YoY
• ▍Free cash flow −38,2% YoY
• ▍Net margin 18.9%

Revenue MYR 64.4M, +1,5% YoY; Operating income −11,8% YoY.

• ▍Revenue MYR 64.4M, +1,5% YoY
• ▍Operating income −11,8% YoY
• ▍Net income −6,1% YoY
• ▍Free cash flow +1,6% YoY
• ▍Net margin 14.6%